Skip to Content
Merck

Broad-spectrum non-nucleoside inhibitors for caliciviruses.

Antiviral research (2017-08-02)
Natalie E Netzler, Daniel Enosi Tuipulotu, Auda A Eltahla, Jennifer H Lun, Salvatore Ferla, Andrea Brancale, Nadya Urakova, Michael Frese, Tanja Strive, Jason M Mackenzie, Peter A White
ABSTRACT

Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and murine norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2′-C-Methylcytidine, ≥95% (HPLC), powder